Loading...
•
Dec 31, 2025
Zymeworks Q4 2025 Earnings Report
Zymeworks Q4 2025 Earnings Report
Key Takeaways
Zymeworks reported a decrease in Q4 revenue compared to the prior year as it transitions clinical activities to partners, while significantly reducing its full-year net loss. The company secured a $250 million royalty-backed note from Royalty Pharma to support its share repurchase program and strategic growth, extending its cash runway beyond 2028.
Secured a $250.0 million non-recourse royalty-backed note financing from Royalty Pharma to support strategic flexibility and share repurchases.
Partner Jazz Pharmaceuticals expects to complete the supplemental BLA for Ziihera in first-line GEA in 1Q 2026 with a potential 2H 2026 launch.
Utilized $62.5 million for share repurchases as of March 2, 2026, under the current $125.0 million authorized program.
Total cash resources of $270.6 million as of year-end 2025, with a runway extended beyond 2028 including anticipated milestones.
Revenue by Segment
Forward Guidance
Zymeworks expects a disciplined framework of approximately $300 million in aggregate adjusted gross operating expenditures over a three-year period ending 2028, with a cash runway extending beyond 2028.
Positive Outlook
- Anticipated $440.0 million in milestone payments for Ziihera GEA approvals in major markets.
- Adjusted gross operating expenses in 2026 expected to be 20% lower than 2025.
- Cash runway funded beyond 2028 including royalty-backed note proceeds.
- Potential commercial launch of Ziihera in first-line GEA in 2H 2026.
- Planned IND filings for multispecific programs ZW209 and ZW1528 in 2026.
Challenges Ahead
- Development-support revenue from Jazz is expected to continue decreasing.
- Greater proportion of the 3-year operating expense budget will be incurred in 2026 compared to 2027-2028.
- Ziihera market authorization in Canada issued with conditions pending trial results.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...